CD19 and B-cell chronic lymphocytic leukemia: Next, we tested the relative cellular specificity of Ro 08-2750, evaluating the number of viable leukemic B (CD19+CD5+) and normal autologous T (CD19−CD5+) cells in CLL patients after exposure in vitro.